Quick Answer
Passage BIO, Inc. reported Research And Development Expense of $23.28 million for the year ending 2025.
- Passage BIO, Inc. showed a decrease of -42.1% in Research And Development Expense from 2024 to 2025.
- This data is from Passage BIO, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $13.12 million | Q1 2024: $11.54 million | Q2 2024: $10.43 million | Q3 2024: $8.66 million | Q1 2025: $7.74 million | Q2 2025: $5.81 million | Q3 2025: $4.31 million.
- Over the full 3 years of available data (2023 to 2025), Passage BIO, Inc.'s Research And Development Expense has declined by 62.1%.
- Historical annual values: Fiscal year 2025: $23.28 million | Fiscal year 2024: $40.18 million | Fiscal year 2023: $61.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: